Publication | Open Access
Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure
84
Citations
20
References
2023
Year
The primary and secondary endpoints of the trial were negative. Positive signals in prespecified, and post hoc exploratory analyses suggest MPCs may improve outcomes, especially in patients with inflammation.
| Year | Citations | |
|---|---|---|
Page 1
Page 1